R&D Productivity Measures Consistently Under-Scored and Under-Valued, EvaluatePharma Data Reveals
London (ots/PRNewswire) - Pharmaceutical R&D productivity is consistently undercounted. Most reports fail to fully count the number of new drugs that reach the market, missing out on billions of dollars of sales generated by R&D investment, an analysis of EvaluatePharma data shows. Most counts of FDA new drug ...